Item 9A. Controls and Procedures
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
As of December 31, 2025, management, with the participation of our Chief Executive Officer (our principal executive officer and principal financial officer), performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a‑15(e) and 15d‑15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures.
Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of December 31, 2025, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of our company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our company’s assets that could have a material effect on the financial statements.
Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management, with the participation of our Chief Executive Officer (principal executive officer and principal financial officer), assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, our management used the criteria set forth in the Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2025 based on those criteria.
179
Table of Contents
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fourth quarter ended December 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information.
There are no disclosures required by this Item 9B, including those relating to “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements,” as those terms are defined in Item 408 of Regulation S-K.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not Applicable.
180
Table of Contents
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
Information required by this item will be included in our Proxy Statement for our 2026 Annual Meeting of Stockholders (the 2026 Proxy Statement) and is incorporated herein by reference.
Our written code of business conduct and ethics (the Code of Conduct) applies to all of our employees, officers and directors, including our principal executive officer, principal financial officer and principal accounting officer or controller. The Code of Conduct is available on our corporate website at https://www.olema.com/ in the Investors section under “Corporate Governance.” If we make any substantive amendments to our Code of Conduct or grant any of our directors or executive officers any waiver, including any implicit waiver, from a provision of our Code of Conduct, we will disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8‑K. Information contained in, or that can be accessed through, our website is not incorporated by reference herein, and you should not consider information on our website to be part of this Annual Report.
Item 11. Executive Compensation.
Information required by this item will be included in our 2026 Proxy Statement and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Information required by this item will be included in our 2026 Proxy Statement and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
Information required by this item will be included in our 2026 Proxy Statement and is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services.
Information required by this item will be included in our 2026 Proxy Statement and is incorporated herein by reference.
181
Table of Contents
PART IV
Item 15. Exhibit and Financial Statement Schedules.
(a) The following documents are filed as part of this Annual Report:
1. Consolidated Financial Statements. See Index to Consolidated Financial Statements in Part II Item 8 of this Annual Report.
2. Consolidated Financial Statement Schedules . None. All financial statement schedules are omitted because they are not applicable, not required under the instructions, or the requested information is included in the financial statements or notes thereto.
3. Exhibits . The following is a list of exhibits filed with this Annual Report or incorporated herein by reference:
Incorporation by Reference
Exhibit
Number
Exhibit
Description
Form
File No.
Exhibit
Filing
Date
Filed
Herewith
3.1
Amended and Restated Certificate of Incorporation.
8‑K
001‑39712
3.1
11/23/2020
3.2
Amended and Restated Bylaws.
8‑K
001‑39712
3.1
12/16/2022
4.1
Form of Common Stock Certificate.
S‑1
333‑249748
4.1
10/30/2020
4.2
Description of Capital Stock.
10-K
001‑39712
4.3
3/17/2021
4.3
Form of Pre-Funded and Exchange
Warrant .
8-K
001-39712
4.1
12/2/2024
4.4
Form of Exchange Warrant .
8-K
001-39712
4.1
1/10/2025
10.1#
Olema Pharmaceuticals, Inc. 2014 Stock Plan, as amended.
S‑1
333‑249748
10.1
10/30/2020
10.2#
Forms of Stock Option Grant Notice, Stock Option Agreement, Early Exercise Stock Purchase Agreement and Notice of Exercise and Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the Olema Pharmaceuticals, Inc. 2014 Stock Plan.
S‑1
333‑249748
10.2
10/30/2020
10.3#
Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan.
S‑1/A
333‑249748
10.3
11/16/2020
10.4#
Forms of Stock Option Grant Notice and Stock Option Agreement under the Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan.
S‑1
333‑249748
10.4
10/30/2020
182
Table of Contents
Incorporation by Reference
Exhibit
Number
Exhibit
Description
Form
File No.
Exhibit
Filing
Date
Filed
Herewith
10.5#
Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan.
S‑1
333‑249748
10.5
10/30/2020
10.6#
Olema Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
S‑1/A
333‑249748
10.6
11/16/2020
10.7#
Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy.
10-Q
001-39712
10.1
8/11/2025
10.8#
Form of Indemnification Agreement by and between the Registrant and its directors and executive officers.
S‑1
333‑249748
10.8
10/30/2020
10.9#
Amended and Restated Offer Letter by and between the Registrant and Sean Bohen, dated November 13, 2020.
S‑1/A
333‑249748
10.9
11/16/2020
10.10#
Amended and Restated Offer Letter by and between the Registrant and Shane Kovacs, dated November 13, 2020.
S‑1/A
333‑249748
10.12
11/16/2020
10.11#
Amended and Restated Offer Letter by and between the Registrant and David Myles, dated November 13, 2020.
S‑1/A
333‑249748
10.14
11/16/2020
10.12¥
Amended and Restated Clinical Collaboration and Supply Agreement by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated January 13, 2022.
10-Q
001-39712
10.1
5/9/2023
10.13
Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated October 9, 2023.
8-K
001-39712
10.1
10/10/2023
10.14#
Olema Pharmaceuticals, Inc. 2022 Inducement Plan, as amended December 5, 2024.
10-K
001-39712
10.14
3/18/2025
183
Table of Contents
Incorporation by Reference
Exhibit
Number
Exhibit
Description
Form
File No.
Exhibit
Filing
Date
Filed
Herewith
10.15#
Form of Stock Option Agreement and Option Grant Notice under the Inducement Plan.
10-K
001-39712
10.18
2/28/2022
10.16#
Offer Letter by and between the Registrant and Naseem Zojwalla, dated December 15, 2021.
10-K
001-39712
10.19
2/28/2022
10.17¥
Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Discovery Technologies Limited, dated June 7, 2022.
10-Q
001-39712
10.1
8/9/2022
10.18#
Offer Letter by and between the Registrant and Shawnte Mitchell, dated January 27, 2025 .
10-K
001-3972
10.18
3/18/2025
10.19
Stock Purchase Agreement by and among the Registrant and the Purchasers named therein, dated September 5, 2023 .
8-K
001-39712
10.1
9/5/2023
10.20
Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated September 5, 2023 .
8-K
001-39712
10.2
9/5/2023
10.21
Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply Agreement by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated March 22, 2024.
10-Q
001-39712
10.1
5/8/2024
10.22
First Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated June 28, 2024.
10-Q
001-39712
10.1
8/6/2024
10.23#
Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy.
10-Q
001-39712
10.2
8/6/2024
184
Table of Contents
Incorporation by Reference
Exhibit
Number
Exhibit
Description
Form
File No.
Exhibit
Filing
Date
Filed
Herewith
10.24
Form of Securities Purchase Agreement by and among the Registrant and the Purchasers named therein, dated November 29, 2024.
8-K
001-39712
10.1
12/2/2024
10.25¥
Clinical Trial Collaboration and Supply Agreement by and between the Registrant and Novartis Pharma AG, dated November 29, 2024.
10-K
001-39712
10.25
3/18/2025
10.26¥
Amendment Number No. 1 to the Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Oncology Limited, dated May 2, 2024 .
10-K
001-39712
10.26
3/18/2025
10.27¥
Amendment Number No. 2 to the Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Oncology Limited, dated November 15, 2024 .
10-K
001-39712
10.27
3/18/2025
10.28
Second Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated June 27, 2025.
10-Q
001-39712
10.2
8/11/2025
10.29¥
Third Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated January 11, 2026.
X
10.30#
Separation and Consulting Agreement by and between the Company and Shane Kovacs.
8-K
001-39712
10.1
1/30/2026
10.31
Sales Agreement by and between Registrant and TD Securities (USA) LLC, dated January 6, 2025.
S-3
333-284146
1.2
1/6/2025
10.32
Amendment No. 1 to Sales Agreement between Olema Pharmaceuticals, Inc. and TD Securities (USA) LLC, dated December 11, 2025.
S-3ASR
333-292079
1.3
12/11/2025
185
Table of Contents
Incorporation by Reference
Exhibit
Number
Exhibit
Description
Form
File No.
Exhibit
Filing
Date
Filed
Herewith
19.1
Olema Pharmaceuticals, Inc. Insider Trading Policy .
10-K
001-39712
19.1
3/18/2025
21.1
Subsidiaries of the Registrant.
X
23.1
Consent of Independent Registered Public Accounting Firm.
X
24.1
Power of Attorney (included on the Signatures page of this Annual Report on Form 10‑K).
X
31.1
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
32.1
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
97.1
Incentive Compensation Recoupment Policy.
10-K
001-39712
97.1
3/11/2024
101.INS
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document
X
101.SCH
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
X
104
Cover Page formatted as Inline XBRL and contained in Exhibit 101
X
# Indicates management contract or compensatory plan or arrangement.
The certification attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
¥ Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the Registrant has determined that the omitted information is the type that the Registrant customarily and actually treats as private or confidential and is not material.
Item 16. Form 10‑K Summary.
None.
186
Table of Contents
SIGN ATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Olema Pharmaceuticals, Inc.
Date: March 16, 2026
By:
/s/ Sean Bohen, M.D., Ph.D.
Sean Bohen, M.D., Ph.D.
President and Chief Executive Officer
187
Table of Contents
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean Bohen, M.D., Ph.D. and Shawnte Mitchell, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10‑K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Name
Title
Date
/s/ Sean Bohen, M.D., Ph.D.
President, Chief Executive Officer and Director
March 16, 2026
Sean Bohen, M.D., Ph.D.
( Principal Executive Officer and Principal Financial Officer )
/s/ Sasha Austin
Vice President, Finance and Controller
March 16, 2026
Sasha Austin
/s/ Ian Clark
Director
March 16, 2026
Ian Clark
/s/ Cynthia Butitta
Director
March 16, 2026
Cynthia Butitta
/s/ Cyrus L. Harmon
Director
March 16, 2026
Cyrus L. Harmon
/s/ Sandra J. Horning, M.D.
Director
March 16, 2026
Sandra J. Horning, M.D.
/s/ Gorjan Hrustanovic, Ph.D.
Director
March 16, 2026
Gorjan Hrustanovic, Ph.D.
/s/ Yi Larson
Director
March 16, 2026
Yi Larson
/s/ Andrew Rappaport
Director
March 16, 2026
Andrew Rappaport
/s/ Graham Walmsley, M.D., Ph.D.
Director
March 16, 2026
Graham Walmsley, M.D., Ph.D.
/s/ Scott Garland
Director
March 16, 2026
Scott Garland
188
Table of Contents
189